Omalizumab In The Treatment Of Refractory Urticarial Vasculitis Triggered By SARS-Cov-2 Infection: A Pediatric Case Report
Keywords:
COVID-19, omalizumab, urticarial vasculitisReferences
Marzano AV, Maronese CA, Genovese G, et al. Urticarial vasculitis: Clinical and laboratory findings with a particular emphasis on differential diagnosis. J Allergy Clin Immunol. 2022;149(4):1137-1149. DOI:10.1016/j.jaci.2022.02.007
Kolkhir P, Grakhova M, Bonnekoh H, Krause K, Maurer M. Treatment of urticarial vasculitis: A systematic review. J Allergy Clin Immunol. 2019;143(2):458-466. DOI:10.1016/j.jaci.2018.09.007
de Perosanz-Lobo D, Fernandez-Nieto D, Burgos-Blasco P, et al. Urticarial vasculitis in COVID-19 infection: a vasculopathy-related symptom? J Eur Acad Dermatol Venereol. 2020;34(10):e566-e568. DOI:10.1111/jdv.16713
Wang S, Fu L, Xiang X, Zhang B, Ma L, Xing H. Successful treatment of urticarial vasculitis with omalizumab in children: a case series. Clin Exp Dermatol. 2023;48(10):1145-1148. DOI:10.1093/ced/llad192
Petrelli F, Giannini D, Bilia S, et al. Efficacy and safety of omalizumab therapy in urticaria vasculitis. Front Allergy. 2022;3:952079. DOI:10.3389/falgy.2022.952079
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Yusuf Can Edek, Ecem Ertürk, Esra Adışen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
